Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System

Buonaguro, 2006, Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses., J. Virol., 80, 9134, 10.1128/jvi.00050-06

Chen, 2020, Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial., JAMA, 323, 1369, 10.1001/jama.2020.2477

2020, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2., Nat. Microbiol., 5, 536, 10.1038/s41564-020-0695-z

Grgacic, 2006, Virus-like particles: passport to immune recognition., Methods, 40, 60, 10.1016/j.ymeth.2006.07.018

Huang, 2017, Escherichia coli-derived virus-like particles in vaccine development., NPJ Vaccines, 2, 10.1038/s41541-017-0006-8

Li, 2010, Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice., Vaccine, 28, 4294, 10.1016/j.vaccine.2010.04.025

Li, 2005, Biosafety level 3 laboratory for autopsies of patients with severe acute respiratory syndrome: principles, practices, and prospects., Clin. Infect. Dis., 41, 815, 10.1086/432720

Li, 2019, Tauroursodeoxycholic acid (TUDCA) inhibits influenza A viral infection by disrupting viral proton channel M2., Sci. Bull., 64, 180, 10.1016/j.scib.2018.08.013

Lopez-Macias, 2012, Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic., Hum. Vaccin Immunother., 8, 411, 10.4161/hv.18757

Low, 2014, Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers., Vaccine, 32, 5041, 10.1016/j.vaccine.2014.07.011

Lythgoe, 2020, Ongoing clinical trials for the management of the COVID-19 Pandemic., Trends Pharmacol. Sci., 41, 363, 10.1016/j.tips.2020.03.006

Mohsen, 2017, Major findings and recent advances in virus-like particle (VLP)-based vaccines., Semin. Immunol., 34, 123, 10.1016/j.smim.2017.08.014

Nie, 2020, Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2., Emerg. Microbes Infect., 9, 680, 10.1080/22221751.2020.1743767

Noad, 2003, Virus-like particles as immunogens., Trends Microbiol., 11, 438, 10.1016/s0966-842x(03)00208-7

Oberemok, 2020, SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship., Inflamm. Res., 69, 635, 10.1007/s00011-020-01352-y

Ou, 2020, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV., Nat. Commun., 11, 10.1038/s41467-020-15562-9

Rabi, 2020, SARS-CoV-2 and Coronavirus Disease 2019: what We Know So Far., Pathogens, 9, 10.3390/pathogens9030231

Santi, 2006, Virus-like particles production in green plants., Methods, 40, 66, 10.1016/j.ymeth.2006.05.020

Shiyu Dai, 2018, Fei Deng. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines., J. Immuno Sci., 2

Wang, 2020, Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2., Cell, 181, 894.e9, 10.1016/j.cell.2020.03.045

Wang, 2020, Comorbidities and multi-organ injuries in the treatment of COVID-19., Lancet, 395, 10.1016/s0140-6736(20)30558-4

Wu, 2020, SARS-CoV-2 is an appropriate name for the new coronavirus., Lancet, 395, 949, 10.1016/s0140-6736(20)30557-2

Zhao, 2012, Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles., Nanomedicine, 8, 1182, 10.1016/j.nano.2012.01.007

Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin., Nature, 579, 270, 10.1038/s41586-020-2012-7